Literature DB >> 1707752

Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.

W B Parker1, S C Shaddix, C H Chang, E L White, L M Rose, R W Brockman, A T Shortnacy, J A Montgomery, J A Secrist, L L Bennett.   

Abstract

2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-adenine (Cl-F-ara-A) has activity against the P388 tumor in mice on several different schedules. Biochemical studies with a chronic myelogenous leukemia cell line (K562) grown in cell culture have been done in order to better understand its mechanism of action. Cl-F-ara-A was a potent inhibitor of K562 cell growth. Only 5 nM inhibited K562 cell growth by 50% after 72 h of continuous incubation. The 5'-triphosphate of Cl-F-ara-A was detected by strong anion exchange chromatography of the acid-soluble extract of K562 cells incubated with Cl-F-ara-A. Competition studies with natural nucleosides suggested that deoxycytidine kinase was the enzyme responsible for the metabolism to the monophosphate. Incubation of K562 cells for 4 h with 50 nM Cl-F-ara-A inhibited the incorporation of [3H]thymidine into the DNA by 50%. Incubation with 0.1, 1, or 10 microM Cl-F-ara-A for 4 h depressed dATP, dCTP, and dGTP pools but did not affect TTP pools. Similar inhibition of deoxyribonucleoside triphosphate pools was seen after incubation with 2-chloro-2'-deoxyadenosine. Both Cl-F-ara-ATP and Cl-dATP potently inhibited the reduction of ADP to dADP in crude extracts of K562 cells (concentration producing 50% inhibition, 65 nM). The effect of Cl-F-ara-ATP on human DNA polymerases alpha, beta, and gamma isolated from K562 cells grown in culture was determined and compared with those of Cl-dATP and 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate (F-ara-ATP). Cl-F-ara-ATP was a potent inhibitor of DNA polymerase alpha. Inhibition of DNA polymerase alpha was competitive with respect to dATP (Ki of 1 microM). The three analogue triphosphates were incorporated into the DNA by DNA polymerase alpha as efficiently as dATP. The incorporation of Cl-F-ara-AMP inhibited the further elongation of the DNA chain, similarly to that seen after the incorporation of F-ara-AMP. Extension of the DNA chain after the incorporation of Cl-dAMP was not inhibited as much as it was with either Cl-F-ara-AMP or F-ara-AMP. Cl-F-ara-ATP was not a potent inhibitor of DNA polymerase beta, DNA polymerase gamma, or DNA primase.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707752

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.

Authors:  Benigno C Valdez; Yago Nieto; David Murray; Yang Li; Guiyun Wang; Richard E Champlin; Borje S Andersson
Journal:  Exp Hematol       Date:  2012-06-09       Impact factor: 3.084

2.  Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.

Authors:  Md Faiz Ahmad; Sarah E Huff; John Pink; Intekhab Alam; Andrew Zhang; Kay Perry; Michael E Harris; Tessianna Misko; Suheel K Porwal; Nancy L Oleinick; Masaru Miyagi; Rajesh Viswanathan; Chris Godfrey Dealwis
Journal:  J Med Chem       Date:  2015-12-09       Impact factor: 7.446

3.  Clofarabine: in pediatric patients with acute lymphoblastic leukemia.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.

Authors:  Yogesh T Patel; Megan O Jacus; Nidal Boulos; Jason D Dapper; Abigail D Davis; Pradeep K Vuppala; Burgess B Freeman; Kumarasamypet M Mohankumar; Stacy L Throm; Richard J Gilbertson; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-28       Impact factor: 3.333

5.  Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Authors:  Amer M Zeidan; Rebecca M Ricklis; Hetty E Carraway; Hyun D Yun; Jacqueline M Greer; B Douglas Smith; Mark J Levis; Michael A McDevitt; Keith W Pratz; Margaret M Showel; Douglas E Gladstone; Steven D Gore; Judith E Karp
Journal:  Br J Haematol       Date:  2012-05-18       Impact factor: 6.998

6.  Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.

Authors:  Kristie A Blum; Mehdi Hamadani; Gary S Phillips; Gerard Lozanski; Amy J Johnson; David M Lucas; Lisa L Smith; Robert Baiocchi; Thomas S Lin; Pierluigi Porcu; Steven M Devine; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-03

7.  Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms.

Authors:  Akshay Sharma; Guolian Kang; Anusha Sunkara; Hiroto Inaba; Sima Jeha; Shane J Cross; Terrence Geiger; Brandon Triplett
Journal:  J Pediatr Hematol Oncol       Date:  2018-11       Impact factor: 1.289

8.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.

Authors:  W B Parker; S C Shaddix; B J Bowdon; L M Rose; R Vince; W M Shannon; L L Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers.

Authors:  Yimon Aye; Edward J Brignole; Marcus J C Long; Johnathan Chittuluru; Catherine L Drennan; Francisco J Asturias; JoAnne Stubbe
Journal:  Chem Biol       Date:  2012-07-27

Review 10.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.

Authors:  Jeffrey C Bryan; Elias J Jabbour
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.